Autism Spectrum Disorder | Treatment Algorithms: Claims Data Analysis | US | 2023
Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder involving significant social, communication, and behavioral challenges. There is no cure for ASD. Behavioral and developmental therapies are the cornerstones of treatment. Pharmacological intervention is used mainly to manage specific symptoms associated with the disease. Only two treatments are FDA-approved for the irritability associated with ASD; all other treatments are used off-label. Our Treatment Algorithms study provides national patient-level claims data to explore the use of key therapies in both newly diagnosed and recently treated patients, providing insight into the current treatment landscape for ASD.
Questions answered
- What patient share do key therapies and brands garner by line of therapy in newly diagnosed ASD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed ASD patients?
- How have atypical antipsychotics been integrated into the treatment algorithm?
- What proportion of ASD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of ASD patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
- What are the product-level compliance and persistency rates among drug-treated patients with ASD?
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Janssen, Otsuka, Eli Lilly
Key drugs: Risperidone, aripiprazole, fluoxetine, sertraline, methylphenidate HCl, lamotrigine, oxcarbazepine, guanfacine, atomoxetine
Solution enhancement
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.
